PRKCB Gene: Protein Kinase C Beta
A key serine/threonine kinase in cell signaling, implicated in cancer, diabetes, and immune disorders.
Gene Information Card
| Symbol | PRKCB |
|---|---|
| Full Name | Protein Kinase C Beta |
| Gene Type | protein-coding |
| Chromosomal Location | 16p12.2 |
| NCBI Gene ID | 5579 ncbi.nlm.nih.gov/gene/5579 |
| Ensembl ID | ENSG00000166501 |
| UniProt ID | P05771 |
| OMIM ID | 176970 |
| HGNC ID | 9395 |
| Aliases | PKC-beta, PKCB, MGC41878 |
Description
PRKCB encodes protein kinase C beta (PKC-β), a calcium-dependent serine/threonine kinase involved in B cell activation, insulin signaling, and vascular function. Alternative splicing produces two isoforms (PKC-βI and PKC-βII) with distinct C-terminal domains. The enzyme is activated by diacylglycerol and phospholipids, and its dysregulation is linked to diabetic complications, cancer progression, and immune dysregulation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Diabetic Nephropathy | Hyperglycemia-induced activation of PKC-β leads to increased vascular permeability and fibrosis | ClinVar, OMIM |
| Diffuse Large B-Cell Lymphoma | PRKCB overexpression promotes B cell survival and proliferation | COSMIC, NCBI |
| Retinopathy of Prematurity | PKC-β mediates VEGF signaling in retinal endothelial cells | OMIM |
| Colorectal Cancer | Gain-of-function mutations enhance Wnt/β-catenin signaling | COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 28.5 | High |
| Spleen | 22.3 | High |
| Lung | 15.1 | Medium |
| Liver | 8.2 | Low |
| Heart | 6.7 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 32.1 | High expression in embryonic kidney cells |
| K-562 | 18.4 | Moderate expression in leukemia cells |
| HeLa | 12.6 | Moderate expression in cervical cancer cells |
| HepG2 | 5.3 | Low expression in liver cancer cells |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1024G>A (p.Glu342Lys) | Missense | 0.02% (COSMIC) | Potential gain-of-function in lymphoma |
| c.1678C>T (p.Arg560Cys) | Missense | 0.01% (ClinVar) | Uncertain significance; reported in diabetes |
| c.1990_1991insA (p.Thr664Asnfs*12) | Frameshift | 0.005% (COSMIC) | Loss-of-function in colorectal cancer |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations (e.g., p.Thr664Asnfs*12) truncate the kinase domain, reducing catalytic activity.
Gain of Function (GOF)
Missense mutations such as p.Glu342Lys increase kinase activity, promoting cell proliferation in lymphomas.
Dominant Negative (DN)
No well-characterized dominant-negative mutations reported in PRKCB.
View complete mutation data：
Gene Ontology (GO)
Pathways
• VEGF signaling pathway (KEGG: hsa04370)
• B cell receptor signaling pathway (KEGG: hsa04662)
• Wnt signaling pathway (KEGG: hsa04310)
• Diabetic complications (Reactome: R-HSA-1980143)
Protein Summary
Protein kinase C beta (PKC-β) is a 673-amino acid enzyme with a regulatory domain (C1 and C2 regions) and a catalytic kinase domain. It is activated by calcium, diacylglycerol, and phosphatidylserine. PKC-β phosphorylates substrates involved in cell growth, differentiation, and apoptosis. Isoform PKC-βII is predominantly nuclear, while PKC-βI is cytosolic. The protein is a therapeutic target in diabetic nephropathy and certain cancers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PRKCB Knockout HEK293 Cell Line | EDJ-KQ584 | Human | 5579 | Details Get a Quote |
| PRKCB Knockout HeLa Cell Line | EDJ-KQ19005 | Human | 5579 | Details Get a Quote |
| PRKCB Knockout A-549 Cell Line | EDJ-KQ62706 | Human | 5579 | Details Get a Quote |
| PRKCB Knockout HCT 116 Cell Line | EDJ-KQ71176 | Human | 5579 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
